Document:

Exhibit 4.5 to N-8A/A as filed August 1, 2003

                               AMENDMENT NO. 4 TO
                      AMENDED AND RESTATED RIGHTS AGREEMENT

Amendment No. 4, dated as of August 4, 2003 ("Amendment No. 4"), between Central
Bancorp,  Inc., a Massachusetts  corporation (the  "Company"),  and Register and
Transfer  Company as rights agent (the "Rights Agent").  Capitalized  terms used
and not otherwise defined herein shall have the meanings ascribed thereto in the
Rights Agreement referenced below.

     WHEREAS,  the Company and the Rights Agent entered into a Rights Agreement,
dated as of October  11,  2001 (as  restated  and  amended to date,  the "Rights
Agreement"); and

     WHEREAS,  the Company  desires to amend the Rights  Agreement in accordance
with Section 5.4.

     NOW, THEREFORE,  in consideration of the premises and mutual agreements set
forth in the Rights Agreement and this Amendment No. 4, the parties hereby agree
as follows:

     1. Definition of Acquiring Person.

     (a)The  definition  of  "Acquiring  Person" set forth in Section 1.1 of the
Rights  Agreement  shall be amended  by  inserting  in  paragraph  (i)  thereof,
following the words "with respect to shares of Common Stock":

     (other than PL Capital,  LLC,  Financial  Edge Fund,  L.P.,  Financial-Edge
     Strategic Fund, L.P.,  Goodbody/PL Capital, L.P., Goodbody/PL Capital, LLC,
     Richard Lashley, John W. Palmer, Richard J. Fates and the Estate of Garrett
     Goodbody  during the  Standstill  Period as defined in the Agreement  dated
     August 4, 2003 among PL Capital, LLC, the Company and others)

     (b) The  definition of  "Acquiring  Person" set forth in Section 1.1 of the
Rights  Agreement  shall be amended  by  inserting  in  paragraph  (i)  thereof,
following then words "during the three year period":

     (which  three year  period  shall be tolled  during the  Standstill  Period
     referenced above for those persons and entities subject to it)

     2. Full Force and Effect. This Amendment No. 4 shall be effective as of the
date hereof.  Except as expressly  amended  hereby,  the Rights  Agreement shall
remain in full force and effect and shall be otherwise unaffected hereby.

     3.  Governing  Law.  This  Amendment No. 4 shall be deemed to be a contract
made under the laws of the  Commonwealth of  Massachusetts  and for all purposes
shall  be  governed  by and  construed  in  accordance  with  the  laws  of such
Commonwealth  applicable to contracts to be made and performed  entirely  within
such Commonwealth.

     4.  Counterparts.  This  Amendment  No. 4 may be  executed in any number of
counterparts and each of such  counterparts  shall for all purposes be deemed to
be an original,  and all such counterparts shall together constitute but one and
the same instrument.

                         (signatures on following page)

     IN WITNESS  WHEREOF,  the  Company  and the Rights  Agent have  caused this
Amendment No. 4 to be duly executed as of the day and year first above written.

                                            CENTRAL BANCORP, INC.

                                            By:/s/John D. Doherty
                                            Name:John D. Doherty
                                            Title:Chairman, President and
                                            Chief Executive Officer

                                            REGISTRAR AND TRANSFER COMPANY

                                            By:/s/William P. Tatler
                                            Name:William P. Tatler
                                            Title:Vice President<PAGE>

Exhibit 10.13
                   AGREEMENT FOR JOINT CLINICAL INVESTIGATIONS

Both sides note that the first treatment of autoimmune diseases by removal of
interferons (cytokines) was proposed in 1974 by Professor S.V. Skurkovich
(Nature, 1974;247:551-2). He also proposed to remove TNF-(alpha) in various
autoimmune conditions, including AIDS (J IFN & Cytokine Res 1989;9:S2 and other
publications and patents). The use of anticytokines in autoimmune conditions has
received wide experimental and clinical confirmation in various laboratories of
the world. As is known, organ transplant rejection is also connected with
autoimmune mechanisms. In joint investigations positive results were obtained
with the use of antibodies to interferon-(gamma) in corneal transplants
(Treatment of corneal transplant rejection in humans with
anti-interferon-(gamma) antibodies,. Am J Opthalmol 2002;133:829-30).

Based on this, the State Institute of Transplantation and Artificial Organs of
the Ministry of Health of the Russian Federation ("Institute" herein) in the
person of the Academician Russian Medical and Professor Valery Ivanovich
Shumakov and Advanced Biotherapy, Inc. (ABI- USA) in the person of Professor
S.V. Skurkovich, vice-president of ABI, agree to conduct joint clinical
investigations on the reduction or prevention of organ transplant rejection by
anticytokine therapy. In our joint investigation mainly anti-interferon-(gamma)
antibodies will be used after transplantation of the heart, lung, liver, or
pancreatic beta-islet cells.

Treatment of other conditions besides transplantation is possible.
ABI will supply the Institute with antibodies to interferon g and antibodies to
TNIF-(alpha) and laboratory reagents (immunological) monitoring in accordance
with a protocol for anticyotkine therapy.

[                                   REDACTED                                 ]

Publications of the results of the clinical trials will be done jointly. ABI has
the right to use the results of the trials as it wishes. The first publications
of the treatment of each condition will be in English and the first author will
be a representation of ABI. Later, if any Russian language reports are
published, the first authors will be members of the Institute.

If the Institute wishes to send a representative to a conference outside of
Russia to present the results of the clinical testing, ABI will pay expenses
(registration, travel and hotel) for one attendee per conference.

This agreement is made and signed in English and Russian languages and has the
same validity.

/s/Simon Skurkovich                /s/Valery Ivanovich Shumakov
-------------------------          ------------------------------------------
on behalf of                       on behalf of
Advanced Biotherapy, Inc.          the State Institute of Transplantation and
                                   Artificial Organs of the Ministry of Health
                                   of the Russian Federation

<PAGE>Exhibit 4A

                              CONSULTING AGREEMENT

CONSULTING AGREEMENT dated June 20, 2003 between DWIGHT LEWIS, of P.O. Box W386,
St. John's, Antigua, West Indies (the "Consultant") and NAPOLI ENTERPRISES, INC.
a corporation duly organized and operating under the laws of the state of
Colorado whose business address is Suite 566 - 1027 Davie Street, Vancouver,
British Columbia, Canada V6C 4L2 ("Napoli").

WHEREAS, Napoli intends to be engaged in the business of wine production and
distribution (the "Business");

AND WHEREAS Napoli wishes to retain the Consultant as an independent contractor,
and the Consultant wishes to be retained in such capacity and to perform certain
services for Napoli to promote the interests of the Business.

NOW THEREFORE, in consideration of the mutual convenants and premises contained
herein and other good and valuable consideration the receipt and sufficiency of
which is hereby acknowledged, the parties agree as follows:

A. CONSULTING

1. Napoli hereby retains the Consultant and Consultant hereby accepts such
engagement, for the term and under the conditions and requirements specified
herein, with such duties and responsibilities as may reasonably be assigned to
pursuant to this Agreement, including research, development, implementation and
management of all "new business" opportunities of Napoli. The Consultant's
compensation shall be that specified below.

2. Consultant's principal duties shall include developing and providing new
business opportunities in the international wine distribution arena with a view
to increasing Napoli's distribution channels. However, the Consultant shall have
no authority to accept, reject or modify any contract entered into by Napoli's
officers or directors, without the express written consent of Napoli.

3. Consultant shall receive compensation, as a recognized executive in the
industry, of One Million and Five Hundred Thousand (1,500,000) fully paid and
non-assessable freetrading shares of common securities of Napoli for the various
services the Consultant performs as required by senior management of Napoli (the
"Compensation"). The Consultant shall bill Napoli for all ordinary, reasonable
and necessary business expenses and Napoli shall pay such amounts, if any, in a
timely manner. Compensation shall become due and payable immediately upon
execution of this Agreement.

4. The Consultant shall devote the Consultant's best efforts, all the times and
places reasonably deemed appropriate to the duties hereunder. However, it is
expressly agreed that the Consultant may serve as a consultant, manager,
investor, or employee to other persons, without limitation.

<PAGE>

5. The principal place of business of the Consultant shall be at such places as
the Consultant, in Consultant's reasonable discretion, may choose from time to
time. The Consultant shall provide not less than 20 days advance notice of any
change in the principal place of business.

B. STATUS OF CONSULTANT

1. The Consultant shall be treated in all respects as an independent contractor
and Napoli shall not withhold any taxes on account of services rendered to it by
the Consultant. The Consultant represents that the Consultant regularly holds
itself out as a consultant to others, maintains its own office, has business
cards other than for services provided to Napoli, and assumes all risk of the
Consultant's classification as an independent contractor and not an employee.

C. TERM OF RETAINER

1. The term for which the Consultant shall be retained hereunder shall commence
on the date hereof and shall terminate upon the earlier of (i) the cessation of
the Business of Napoli; (ii) the death or substantial disability of the
Consultant; or (iii) the last day of the sixth month following the date of this
Agreement. However, notwithstanding anything herein to the contrary, this
Agreement shall terminate on June 19, 2004.

D. EXTENSION, TERMINATION AND ARBITRATION

1. If the Consultant shall be terminated by Napoli, the Consultant shall be
entitled to any amounts due and owing as compensation under their Agreement to
the extent earned, as defined herein, on a pro-rata basis beyond the period
covered by the initial issuance of shares, plus reimbursement for ordinary,
reasonable and necessary expenses incurred prior to termination.

2. If the Consultant's engagement by Napoli is terminated for any reason, the
Consultant agrees to protect the value of Napoli's Confidential Information and
Inventions and will prevent their misappropriation or disclosure. The Consultant
agrees not to disclose any Confidential Information or Inventions for the
Consultant's benefit or the benefit of any third party, or to the detriment of
Napoli or its clients.

3. Any disputes arising between the Consultant and Napoli shall be settled by
Arbitration in the State and under the Laws of Colorado.

E. DISABILITY OR DEATH

1. The Consultant shall be deemed substantially disabled if (i) the Consultant
and Napoli agree that the Consultant is substantially disabled; (ii) for a
period of thirty (30) consecutive days, the Consultant is unable, as a result of
any physical, mental or emotional illness, ailment, or accident effectively
discharge the Consultant's duties

<PAGE>

hereunder. If the Consultant shall be substantially disabled as defined herein,
Napoli may then immediately upon notice to the Consultant terminate this
Agreement and Napoli's obligation to pay the Consultant the Compensation will
likewise terminate.

F. EXPENSES

1. Napoli shall be responsible for any and all ordinary, reasonable and
necessary expenses which the Consultant incurs in performing the duties assigned
hereunder. The Consultant shall be responsible to provide reasonable
corroboration to Napoli of any such expenses.

H. MISCELLANEOUS

1. This Agreement constitutes the entire agreement between the parties hereto,
supercedes all existing agreements between them, and cannot be changed or
terminated except by a written agreement, signed by all parties and may not be
assigned by either party.

2. This Agreement shall be construed in accordance with the substantive law of
Colorado.

EXECUTED FOR AN ON BEHALF of the parties on the date first written above.

                                        NAPOLI ENTERPRISES, INC.,
CONSULTANT

/s/ Dwight Lewis                        /s/ Greg Sonic,
------------------------------          ----------------------------------------
Name: Dwight Lewis                      Name: Greg Sonic, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]